Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential
Xenon(XENE) Seeking Alpha·2025-01-16 06:41Xenon Pharmaceuticals Inc. (NASDAQ: XENE ) is researching epilepsy therapies and other neuropsychiatric treatments. Currently, their leading candidate is Azetukalner, which is intended for FOS, PGTCS, and MDD. The interesting thing about its mechanism of action is that it targets Kv7 potassiumMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, ...